GlassScriptPhysician profile
Omid Amidi
NPI 1164950689
$4,356.32
in general payments reported to CMS, 2019-2025
25 companies · $403 in 2025
The $403 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $668 · 2024: $3,286 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,273 · Education: $83.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,272.93 |
| Education | $83.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $863.26 | 2023-2025 | Bodyguardian, Resonate El Icd Vr, Emblem Mri S-Icd |
| Novo Nordisk INC | $630.33 | 2024 | Wegovy, Ozempic, Rybelsus |
| Arcutis Biotherapeutics, INC. | $577.09 | 2024-2025 | Zoryve |
| Amgen INC. | $306.30 | 2023-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.16 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $222.28 | 2024 | |
| Merck Sharp & Dohme LLC | $186.16 | 2023-2024 | Verquvo |
| Heartflow, INC. | $164.95 | 2024 | |
| Shockwave Medical, INC | $148.59 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Esperion Therapeutics, INC. | $142.67 | 2023-2024 | Nexletol, Nexlizet |
| Pfizer INC. | $120.35 | 2024 | |
| Alnylam Pharmaceuticals INC. | $98.56 | 2024 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $81.00 | 2023-2024 | Inpefa |
| W. L. Gore & Associates, INC. | $72.46 | 2025 | Gore Cardioform Septal Occluder |
| Astrazeneca Pharmaceuticals LP | $71.55 | 2024 | Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $68.71 | 2024 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $67.31 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $62.49 | 2024 | Xarelto |
| Scpharmaceuticals INC. | $45.27 | 2023 | |
| Ucb, INC. | $29.37 | 2024 | Cimzia |
| Abbott Laboratories | $29.10 | 2024 | Mitraclip |
| Kiniksa Pharmaceuticals, LTD. | $25.30 | 2023 | Arcalyst |
| Lilly USA, LLC | $19.78 | 2024 | Zepbound |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.43 | 2024 | Lifevest |
| Medtronic, INC. | $14.85 | 2023 | Corevalve Evolut R |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Amidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.